Can I still proceed with my in vitro antifungal activity with low encapsulation efficiencies?

Hello Portia,

If you want to proceed with the in vitro antifungal activity of your encapsulated active ingredient, I suggest you to purify the formulation in order to get rid of the non encapsulated Cithral. There is different methods for nanoparticle purification, like ultracentrifugation, ultrafiltration, TFF (tangential flow filtration), dyalisis..

You should keep the purified nanoparticles, analyse the active ingredient content after purification with HPLC or another technique after extraction of the Cithral, and use this purified fraction for your experiment. You should compare the efficacy of the nanoencapsulated Cithral, with a Cithral control solution (without nanoparticles) at the same concentration, in order to study the nanovehicle effect.

If you use the unpurified nanoformulation with such a low EE%, probably you will see no diference in efficacy as compared with the Cythral control solution.

Best regards,

Eloy

Abdullah S. Seddiek

The encapsulation efficiency of a compound refers to the percentage of the compound that is successfully encapsulated within a delivery system or carrier. In the context of antifungal activity, if you are using a delivery system or carrier to encapsulate an antifungal agent, low encapsulation efficiencies may affect the performance and effectiveness of your in vitro antifungal activity.

Here are a few factors to consider when proceeding with in vitro antifungal activity despite low encapsulation efficiencies:

Drug Concentration: If your encapsulation efficiency is low, it means that a significant portion of the antifungal agent is not being encapsulated and may not be available for interaction with the fungal cells. This can lead to lower effective drug concentrations in your test system. Adjusting the concentration of the encapsulated drug may help compensate for the low encapsulation efficiency and increase the overall antifungal activity.

Control Group: Include a control group in your experiment where you test the antifungal agent without encapsulation. This will allow you to compare the activity of the encapsulated formulation to the unencapsulated form. By assessing the difference in antifungal activity, you can determine the contribution of the encapsulation process and evaluate the effectiveness of the encapsulated formulation.

Comparative Studies: Conduct comparative studies with different encapsulation techniques or carrier systems to identify the most effective approach for encapsulating the antifungal agent. It's possible that different encapsulation methods may yield higher encapsulation efficiencies and better antifungal activity.

Characterization: Perform thorough characterization of your encapsulated formulation to understand the factors contributing to low encapsulation efficiency. Analyze the physicochemical properties of the carrier system, such as particle size, surface charge, and morphology, to identify any potential limitations or issues that could impact the antifungal activity.

Optimization: If feasible, consider optimizing the encapsulation process to improve the encapsulation efficiency. This may involve adjusting parameters such as concentration, formulation components, encapsulation method, or process conditions to enhance the encapsulation process and increase the overall efficiency.

It is important to note that the specific impact of low encapsulation efficiency on your antifungal activity will depend on the characteristics of the antifungal agent, the delivery system, and the target fungal species. Therefore, it is recommended to conduct preliminary experiments and evaluate the performance of the encapsulated formulation in comparison to the unencapsulated form to assess the potential impact on antifungal activity.

Consulting with experts in the field or conducting additional literature research specific to your encapsulation system and antifungal agent can provide further insights and guidance in addressing the issue of low encapsulation efficiency in your in vitro antifungal activity.

Would anyone be able to provide me with the book with the title Globalization: A Very Short Introduction?

How has Globalization affected development in the Global South?

What emotional safety protocols can be put in place as "first aids" to deal with our anxieties and fears owing to Covid-19?

Is lentiviral production of antibodies in 293T viable?

How can I measure point of zero charge?

How do you quantify transwell invasion assays after staining with crystal violet? Anything else apart from counting cells manually?

Does P. berghei always appear as ring shape when observed under the microscope?

Any suggestions on finding homologous of ncRNA between rats and human?

In performing Fluorescent Sandwich ELISA using a fluorophore-conjugated detection antibody, do I need to wash the wells prior to plate reading?

Storage of DNA from excised gel

I need to image mesoporous silica nanoparticles that are in ~100 nm size and do high resolution TEM to look at mesopores. what grids should I use?

Does Napabucasin soluble in dichloromethane and in ethanol?

Can chitosan alone can act as a reducing agent for Cu(0) nanoparticle sythesis?

What are the new 2D nanomaterials were used for Silver nanoparticles stabilization?

What is the state of the drug inside solid lipid nanoparticles (SLNs)?

How to check the uv-vis absorption of nanoparticle by surface plasmon resonance?

Distribution of particles in metal matrix?

How can I calculate the rdf of water molecules around 'Na' ions that are closest(adsorbed) to the nanoparticle(solute)?

LEDs on Vis Light photo degradation of MB water sol via N doped TiO2 in a mini flume?

Can anyone share his experience regards Smoothing in origin?